Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Ideanomics Inc

China Rapid Finance

As September turns bullish for penny stocks, which small-caps are on your watchlist? The post 3 Top Penny Stocks That You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks That You Need to Know About Right Now

Today, JAGX stock is surging higher on news of executive appointments, as well as the company's recent reverse stock split. The post JAGX Stock: What Is Going on With Jaguar Health Today?

JAGX Stock: What Is Going on With Jaguar Health Today?

Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the appointment of Karen J.

Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director

Document Security Systems

Globalstar

Why top penny stock investors are watching these hot small-caps right now The post Hot Penny Stocks That Top Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Top Investors Are Watching Right Now

Jaguar Health, Inc. (NASDAQ:JAGX) had recently announced a 1-for-3 reverse stock split, which has now gone into effect. These are the details.

JAGX Stock: 1-For-3 Reverse Split Goes Into Effect

Jaguar Health Inc (NASDAQ: JAGX) will effect a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-3. The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on September 8.

Jaguar Health Stock Is Trading Lower In Reaction To Reverse Stock Split

Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders Shares of Jaguar common stock to begin trading on split-adjusted basis on September 8, 2021 SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-3, on Wednesday, September 8, 2021 (the "Effective Date"). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol "JAGX".

Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split

Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 2021 Annual Meeting of Stockholders, which was adjourned until September 3, 2021. Six items of business were addressed at the meeting today: Proposal 1: To elect one Class III director.

Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders

Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (Mytesi®) on the gastrointestinal microbiome in people living with HIV/AIDS (PLWHA) has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3. Mytesi (crofelemer) is an antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting

CytoDyn Inc.

9 Meters Biopharma

Biotech penny stocks are heating up right now, here's 3 for next month's watchlist The post Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Right Now? 3 to Watch Next Month

Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is eligible to receive additional payments related to milestones, royalties, and product transfers Napo EU's initial focus is on accelerated conditional approval for orphan disease: short bowel syndrome with intestinal failure SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Napo Pharmaceuticals, Inc. (Napo), the wholly owned US subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the signing of a license agreement with Napo's Italian subsidiary, Napo EU S.p.A.

Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe

AcelRx Pharmaceuticals

ReShape Lifesciences

Tellurian

22nd Century Group

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021

In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported by the National Institute of Allergy and Infectious Diseases for four studies SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2021 / Napo Pharmaceuticals, Inc. ("Napo"), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), announced today the completion of an additional preclinical toxicology study intended to support continued development of NP-300 (lechlemer) for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions. The study findings support the Investigational New Drug (IND) application Napo plans to file for lechlemer for this indication in the first half of 2022.

Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q2 2021 Results - Earnings Call Transcript

Second quarter 2021 Mytesi ® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty pharmacies as part of Company's market access strategy Company to host investor webcast Friday, August 13th at 8:00 a.m. Eastern regarding second quarter 2021 financials & business updates; Webcast registration link appears below SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated second quarter 2021 financial results.

Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results

Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).

Recap: Jaguar Health Q2 Earnings

Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.

Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time

Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day SAN FRANCISCO, CA / ACCESWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Friday, August 13, 2021 at 8:30 a.m. Eastern Time to review second-quarter 2021 financials and provide business updates.

Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates

Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a fourth time due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote

Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, and member of the board of directors of Napo EU S.p.A., will be aired during an investor webcast tomorrow (Thursday, July 29, 2021) at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A.

REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates

Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, will be aired during an investor webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A.

Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates

Asensus Surgical

Why these biotech penny stocks are seeing heightened momentum right now The post Could These Biotech Penny Stocks Explode in August 2021? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Could These Biotech Penny Stocks Explode in August 2021?

Aquestive Therapeutics Inc

Support.com

Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Stocks To Watch With The Stock Market Down Today

Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the US FDA for SBS) Merger of Napo EU & Dragon SPAC expected to be effective within approximately 80 days, with related future SBS license and milestone fees totaling up to $12.5 million MILAN, ITALY and SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2021 / Dragon SPAC S.p.A. and Napo EU S.p.A.

Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A.

Yamana Gold

Express

Genius Brands

Are These Penny Stocks Worth Adding to Your Watchlist in July 2021? The post 4 Penny Stocks That Are Worth Adding to Your Watchlist in July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Jaguar Health Stock (JAGX)